Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
NCT05253131
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
41
Enrollment
OTHER
Sponsor class
Conditions
MPNST
NF1
Sarcoma
Interventions
COMBINATION_PRODUCT:
Selumetinib + ZEN-3694 ± Durvalumab
Sponsor
University of Alabama at Birmingham
Collaborators
[object Object]
[object Object]